Hansa Biopharma Balance Sheet Health

Financial Health criteria checks 1/6

Hansa Biopharma has a total shareholder equity of SEK-167.9M and total debt of SEK844.9M, which brings its debt-to-equity ratio to -503.3%. Its total assets and total liabilities are SEK1.0B and SEK1.2B respectively.

Key information

-503.3%

Debt to equity ratio

kr844.90m

Debt

Interest coverage ration/a
Cashkr732.06m
Equity-kr167.88m
Total liabilitieskr1.19b
Total assetskr1.02b

Recent financial health updates

Recent updates

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Feb 07
Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Dec 28
Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Oct 13
Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Sep 22
Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

May 31
Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt

Apr 03
Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt

Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Feb 06
Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

Feb 01
Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

We're Keeping An Eye On Hansa Biopharma's (STO:HNSA) Cash Burn Rate

Mar 23
We're Keeping An Eye On Hansa Biopharma's (STO:HNSA) Cash Burn Rate

Financial Position Analysis

Short Term Liabilities: HNSA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: HNSA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: HNSA has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: HNSA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HNSA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: HNSA has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 23% each year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.